VEGF in physiological process and thyroid disease

Annales d'Endocrinologie

Volumn 68, Issue 6, 2007, Pages 438-448

  Klein, M ^a   Catargi, B ^b  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

Angiogenesis; Cancer; Goiter; Thyroid; Thyroiditis; Vascular endothelial growth factor; VEGF

Indexed keywords

3 (4 BROMO 2,6 DIFLUOROBENZYLOXY) 5 [3 [4 (1 PYRROLIDINYL)BUTYL]UREIDO] 4 ISOTHIAZOLECARBOXAMIDE; 4 (4 FLUORO 2 METHYL 5 INDOLYLOXY) 6 METHOXY 7 [3 (1 PYRROLIDINYL)PROPOXY]QUINAZOLINE; 5,6,7,13 TETRAHYDRO 12 (3 HYDROXYPROPYL) 9 ISOPROPOXYMETHYLINDENO[2,1 A]PYRROLO[3,4 C]CARBAZOL 5(12H) ONE DIMETHYLGLYCINE ESTER; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; AG 13925; ANGIOGENESIS INHIBITOR; AXITINIB; BAY 934006; BEVACIZUMAB; CDP 791; GW 786024; IMC 1121B; MANUMYCIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY A4.61; N (3,3 DIMETHYL 6 INDOLINYL) 2 (4 PYRIDINYLMETHYLAMINO)NICOTINAMIDE; NEUROPILIN; PACLITAXEL; PLACENTAL GROWTH FACTOR; PROTEIN TYROSINE KINASE INHIBITOR; SNAKE VENOM; SUNITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN E; VASCULOTROPIN F; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; VATALANIB; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN; VEGFB PROTEIN, HUMAN; VEGFC PROTEIN, HUMAN;

ANGIOGENESIS; BLOOD VESSEL; CERVICAL LYMPH NODE; CORRELATION ANALYSIS; EMBRYO DEVELOPMENT; GOITER; GRAVES DISEASE; HUMAN; LYMPHANGIOGENESIS; MENSTRUAL CYCLE; METASTASIS; NONHUMAN; PARAPOXVIRUS; PATHOLOGY; PERINATAL PERIOD; PHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN TARGETING; REGULATORY MECHANISM; SHORT SURVEY; THYROID CELL; THYROID DISEASE; THYROID GLAND; THYROID PAPILLARY CARCINOMA; THYROID TUMOR; THYROIDITIS; TUMOR GROWTH; WOUND HEALING; PATHOPHYSIOLOGY; REVIEW;

HUMANS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; THYROID DISEASES; THYROID GLAND; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR B; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR D;

EID: 36549072418     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ando.2007.09.004     Document Type: Short Survey

References (128)

1. Adamis A.P., Miller J.W., Bernal M.-T., D'Amico D., Folkman J., Yeo T.-K., et al. Increased vascular endothelial growth factor in the vitreous of eyes with proliferative diabetic retinopathy. Am. J. Ophthalmol. 118 (1994) 445-450
2. Aiello L.P., Avery R.L., Arrigg P.G., Keyt B.A., Jampel H.D., Shah S.T., et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med. 331 (1994) 1480-1487 [see comments]
3. Akslen L., and Livolsi V. Increased angiogenesis in papillary thyroid carcinoma but lack of prognostic importance. Hum. Pathol. 31 (2000) 439-442
4. Baker P.N., Krasnow J., Roberts J.M., and Yeo K.T. Elevated serum levels of vascular endothelial growth factor in patients with pre-eclampsia. Obstet. Gynecol. 86 (1995) 815-821
5. Bauer A., Patel A., Terrell R., Doniparthi K., Saji M., Ringel M., et al. Systemic administration of vascular endothelial growth factor monoclonal antibody reduces the growth of papillary thyroid carcinoma in a nude mouse model. Ann. Clin. Lab. Sci. 33 (2003) 192-199
6. Bauer A., Terrell R., Doniparthi N., Patel A., Tuttle R., Saji M., et al. Vascular endothelial growth factor monoclonal antibody inhibits growth of anaplastic thyroid cancer xenografts in nude mice. Thyroid 12 (2002) 953-961
7. Belletti B., Ferraro P., Arra C., et al. Modulation of in vivo growth of thyroid tumor-derived cell lines by sense and antisense vascular endothelial growth factor gene. Oncogene 18 (1999) 4860-4869
8. Ben-Av P., Crofford J.L., Wilder R.L., and Hla T. Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. FEBS Lett. 372 (1995) 83-87
9. Bikfalvi A., Javerzat S., Perollet C., and Savona C. Angiogenesis and cancer. Bull. Cancer 84 (1997) 885-890
10. Blood C.H., and Zetter B.R. Tumor interactions with the vasculature: angiogenesis and tumor metastasis. Biochim. Biophys. Acta 1032 (1990) 89-118
11. Borgström P., Hillan K.J., Sriramoa S., and Ferrara N. Complete inhibition of angiogenesis and growth of microtumors by antivascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res. 56 (1996) 4032-4039
12. Borgström P., Gold D.P., Hillan K.J., and Ferrara N. Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res. 19 5B (1999) 4203-4214
13. νβ3 antagonists blocks human breast cancer growth and angiogenesis in human skin. J. Clin. Invest. 96 (1995) 1815-1822
14. Brown L.F., Detmar M., Claffey K., Nagy J.A., Feng A., Dvorak A.M., et al. Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. In: Goldberg I.D., and Rosen E.M. (Eds). Regulation of angiogenesis (1997), Birkhäuser, Basel, Boston, Berlin 233-269
15. Brown L.F., Olbricht S.M., Berse B., Jackman R.W., Matsueda G., Tognazzi K.A., et al. Overexpression of vascular permeability factor (VPF/VEGF) and its endothelial cell receptors in delayed hypersensitivity skin reactions. J. Immunol. 154 (1995) 2801-2807
16. Brown L.F., Yeo K.-T., Berse B., Yeo T.-K., Senger D.R., Dvorak H.F., et al. Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J. Exp. Med. 176 (1992) 1375-1379
17. Bunone G., Vigneri P., Mariani L., Buto S., Collini P., Pilotti S., et al. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am. J. Pathol. 155 (1999) 1967-1976
18. Claffey K.P., Wilkison W.O., and Spiegelman B.M. Vascular endothelial growth factor. Regulation by cell differentiation and activated second messenger pathways. J. Biol. Chem. 267 (1992) 16317-16322
19. Cohen T., Nahari D., Cerem L.W., Neufeld G., and Levi B.Z. Interleukin 6 induces the expression of vascular endothelial growth factor. J. Biol. Chem. 271 (1996) 736-741
20. Cornali E., Zietz C., Benelli R., Weninger W., Masiello L., Breier G., et al. Vascular endothelial growth factor regulates angiogenesis and vascular permeability in Kaposi's sarcoma. Am. J. Pathol. 149 (1996) 1851-1869
21. Cullinann-Bove K., and Koos R. Vascular endothelial growth factor/vascular permeability factor expression in the rat uterus: Rapid stimulation by estrogen correlates with estrogen-induced increases in uterine capillary permeability and growth. Endocrinology 133 (1993) 829-837
22. Desai J., Yassa L., Marqusee E., George S., Frates M.C., Chen M., et al. Hypothyroidism after Sunitinib Treatment for Patients with Gastrointestinal Stromal Tumors. Ann. Intern. Med. 145 (2006) 660-664
23. Detmar M., Brown L.F., Claffey K.P., Yeo K.T., Kocher O., Jackman R.W., et al. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptor in psoriasis. J. Exp. Med. 180 (1994) 1141-1146
24. Dhar D., Kubota H., Kotoh T., Tabara H., Watanabe R., Tachibana M., et al. Tumor vascularity predicts recurrence in differentiated thyroid carcinoma. Am. J. Surg. 176 (1998) 442-447
25. Dolecki G.J., and Connolly D.T. Effects of a variety of cytokines and inducing agents on vascular permeability factor mRNA levels in U937 cells. Biochem. Biophys. Res. Commun. 180 (1991) 572-578
26. Fafeur V., Vandenbunder B., and Stéhelin D. Le processus métastatique. Rev. Prat. 45 (1995) 1460-1467
27. Fava R.A., Olsen N.J., Spencer G.G., Yeo K.T., Yeo T.K., Berse B., et al. Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J. Exp. Med. 180 (1994) 341-346
28. Fellmer P., Sato K., Tanaka R., Okamoto T., Kato Y., Kobayashi M., et al. Vascular endothelial growth factor-C gene expression in papillary and follicular thyroid carcinomas. Surgery 126 (1999) 1056-1061
29. Fenton C., Patel A., Dinauer C., Robie D.K., Tuttle R.M., and Francis G.L. The expression of vascular endothelial growth factor and the type 1 vascular endothelial growth factor receptor correlate with the size of papillary thyroid carcinoma in children and young adults. Thyroid 10 (2000) 349-357
30. Ferrara N. Vascular endothelial growth factor: the trigger for neovascularization in the eye. Lab. Invest. 72 (1995) 615-618
31. Ferrara N., and Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr. Rev. 18 (1997) 4-25
32. Ferrara N., and Henzel W.J. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun. 161 (1989) 851-858
33. Ferrara N., Winer J., Burton T., Rowland A., Siegel M., Phillips H.S., et al. Expression of vascular endothelial growth factor does not promote transformation but confers a growth advantage in vivo to Chinese hamster ovary cells. J. Clin. Invest. 91 (1993) 160-170
34. Finkenzeller G., Marme D., Weich H.A., and Hug H. Platelet-derived growth factor induced transcription of the vascular endothelial growth factor gene is mediated by protein kinase C. Cancer Res. 52 (1992) 4821-4823
35. Fischer S., Sharma H.S., Karliczek G.F., and Schaper W. Expression of vascular permeability factor/vascular endothelial growth factor in pig cerebral microvascular endothelial cells and its upregulation by adenosine. Brain Res. Mol. Brain Res. 28 (1995) 141-148
36. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285 (1971) 1182-1186
37. Folkman J. The role of angiogenesis in tumor growth. Semin. Cancer Biol. 3 (1992) 65-71
38. Folkman J. Angiogenesis and angiogenesis inhibition: an overview. In: Goldberg I.D., and Rosen E.M. (Eds). Regulation of angiogenesis (1997), Birkhäuser, Basel, Boston, Berlin 1-8
39. Folkman J., and Haudenschild C. Angiogenesis in vitro. Nature 288 (1980) 551-556
40. Folkman J., and Klagsbrun M. Angiogenic factors. Science 235 (1987) 442-447
41. Folkman J., Watson K., Ingber D., and Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339 (1975) 58-61
42. Fontanini G., Vignati S., Pacini F., Pollina L., and Basolo F. Microvessel count: an indicator of poor outcome in medullary thyroid carcinoma but not in other types of thyroid carcinoma. Mod. Pathol. 9 (1996) 636-641
43. Fregene T., Khanuja P.S., Noto A., Gehani S., Egmaont E., Luz D., et al. Tumor associated angiogenesis in prostate cancer. Anticancer Res. 13 (1993) 1377-1382
44. Garrido C., Saule S., and Gospodarowicz D. Transcriptional regulation of vascular endothelial growth factor gene expression in ovarian bovine granulosa cells. Growth Factors 8 (1993) 109-117
45. Gasparini G., Weidner N., Maluta S., Pozza F., Mezzeth M., Testolin A., et al. Intratumoral microvessel density and p53 protein correlation with metastasis in head and neck squamous cell carcinoma. Int. J. Cancer 55 (1993) 739-744
46. Gimbrone M., Leapman S., Cotrans R., and Folkman J. Tumor dormancy in vitro by prevention of neovascularization. J. Exp. Med. 136 (1972) 261-276
47. Goldberg M.A., and Schneider T.J. Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin. J. Biol. Chem. 269 (1994) 4355-4361
48. Goldenberg J., Portugal L., Wenig B., Ferrer K., Wu J., and Sabnani J. Well-differentiated thyroid carcinomas: p53 mutation status and microvessel density. Head Neck 20 (1998) 152-158
49. Goodmann A., and Rone J. Thyroid angiogenesis: endotheliotropic chemi-attractant activity from rat thyroid cells in culture. Endocrinology 121 (1987) 2131-2140
50. Graham C.H., Rivers J., Kerbel R.S., Stankiewicz K.S., and White W.L. Extent of vascularization as a prognostic indicator in thin (< 0.76 mm) malignant melanoma. Am. J. Pathol. 145 (1994) 510-514
51. Grugel S., Finkenzeller G., Barleon B., Weindel K., and Marme D. Both v-Ha-ras and v-raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells. J. Biol. Chem. 270 (1995) 25915-25919
52. Harada S., Nagy J.A., Sullivan K.A., Thomas K.A., Endo N., Rodan G.A., et al. Induction of vascular endothelial growth factor expression by prostaglandin E2 and E1 in osteoblasts. J. Clin. Invest. 93 (1994) 2490-2496
53. Hayes D.F. Angiogenesis and breast cancer. Hematol. Oncol. Clin. North Am. 8 (1994) 51-71
54. Herrmann G., Schumm-Draeger P., Muller C., Atai E., Wenzel B., Fabian T., et al. T lymphocytes, CD68-positive cells and vascularisation in thyroid carcinomas. J. Cancer Res. Clin. Oncol. 120 (1994) 651-656
55. Hirschi K.K., and D'Amore P.A. Control of angiogenesis by the pericyte: molecular mechanisms and significance. In: IDGAEM R. (Ed). Regulation of angiogenesis (1997), Basel, Birkhäuser Verlag 419-428
56. Hung C., Ginzinger D., Zarnegar R., Kanauchi H., Wong M., Kebebew E., et al. Expression of Vascular Endothelial Growth Factor-C in Benign and Malignant Thyroid Tumors. J. Clin. Endocrinol. Metab. 88 (2003) 3694-3699
57. Hyder S.M., Murthy L., and Stancel G.M. Progestin regulation of vascular endothelial growth factor in human breast cancer cells. Cancer Res. 58 (1998) 392-395
58. Iitaka M., Miura S., Yamanaka K., Kawasaki S., Kitahama S., Kawakami Y., et al. Increased serum vascular endothelial growth factor levels and intrathyroidal vascular area in patients with Graves' disease and Hashimoto's thyroiditis. J. Clin. Endocrinol. Metab. 83 (1998) 3908-3912
59. Iliopulos O., Levy A.P., Jiang C., Kaelin W.G., and Goldberg M.A. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc. Natl. Acad. Sci. USA 93 (1996) 10595-10599
60. Ishiwata T., Iino Y., Takei H., Oyama T., and Morishita Y. Tumor angiogenesis as an independent prognostic indicator in human papillary thyroid carcinoma. Oncol. Rep. 5 (1998) 1343-1348
61. Kamat B.R., Brown L.F., Manseau E.J., Senger D.R., and Dvorak H.F. Expression of vascular permeability factor/vascular endothelial growth factor by human granulosa and theca lutein cells. Role in corpus luteum development. Am. J. Pathol. 146 (1995) 157-165
62. Katoh R., Miyagi E., Kawaoi A., Hemmi A., Komiyama A., Oyama T., et al. Expression of vascular endothelial growth factor (VEGF) in human thyroid neoplasm. Hum. Pathol. 30 (1999) 891-897
63. Kieser A., Weich H.A., Brandner G., Marme D., and Kolch W. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 9 (1994) 963-969
64. Kilicarslan A., Ogus M., Arici C., Pestereli H., Cakir M., and Karpuzoglu G. Clinical importance of vascular endothelial growth factor (VEGF) for papillary thyroid carcinomas. APMIS 111 (2003) 439-443
65. Kim K.J., Li B., Houck K.A., Winer J., and Ferrara N. The vascular endothelial growth factor proteins: Identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 7 (1992) 53-64
66. Kim K.J., Li B., Winer J., Armanini M., Gillett N., Phillips H.S., et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362 (1993) 841-844
67. Klagsbrun M., and D'Amore P.A. Regulators of angiogenesis. Ann. Rev. Physiol. 53 (1991) 217-239
68. Klein M., Brunaud L., Muresan M., Barbé F., Marie B., Sapin R., et al. Recombinant human thyrotropin stimulates thyroid angiogenesis in vivo. Thyroid 16 (2006) 531-536
69. Klein M., Picard E., Vignaud J.-M., Marie B., Bresler L., Toussaint B., et al. Vascular endothelial growth factor gene and protein: strong expression in thyroiditis and thyroid carcinoma. J. Endocrinol. 161 (1999) 41-49
70. Klein M., Vignaud J., Hennequin V., Tousaint B., Bresler L., Plenat F., et al. Increased expression of the vascular endothelial growth factor is a pejorative marker in papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 86 (2001) 656-658
71. Koch A.E., Harlow L.A., Haines G.K., Amento E.P., Unemori E.N., Wong W.L., et al. Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J. Immunol. 152 (1994) 4149-4156
72. Koos R.D. Increased expression of vascular endothelial growth factor/vascular permeability factor in the rat ovary, following an ovulatory gonadotropin stimulus: potential roles in follicle rupture. Biol. Reprod. 52 (1995) 1426-1435
73. Ladoux A., and Frelin C. Hypoxia is a strong inducer of vascular endothelial growth factor mRNA expression in the heart. Biochem. Biophys. Res. Commun. 195 (1993) 1005-1010
74. Ladoux A., and Frelin C. Cobalt stimulates the expression of vascular endothelial growth factor mRNA expression in rat cardiac cells. Biochem. Biophys. Res. Commun. 204 (1994) 794-798
75. Larsen K., Andersen N.F., Melsen F., and Brand Sorensen F. Vascularity in thyroid neoplasms: a methodological investigation with a view to diagnostics. APMIS 114 (2006) 749-756
76. Lennard C., Patel A., Wilson J., Reinhardt B., Tuman C., Fenton C., et al. Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer. Surgery 129 (2001) 552-558
77. Li J., Perrella M.A., Tsai J.C., Yet S.F., Hsieh C.M., Yoshizumi M., et al. Induction of vascular endothelial growth factor gene expression by interleukin-1 beta in rat aortic smooth muscle cells. J. Biol. Chem. 270 (1995) 308-312
78. Lin S., Wang Y., and Sheu W. Preoperative plasma concentrations of vascular endothelial growth factor and matrix metalloproteinase 9 are associated with stage progression in papillary thyroid cancer. Clin. Endocrinol. (Oxf.) 58 (2003) 513-518
79. Malecaze F., Clemens S., Simorer-Pinotel V., Mathis A., Chollet P., Favard P., et al. Detection of vascular endothelial growth factor mRNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. Arch. Ophthalmol. 112 (1994) 1476-1482
80. Mazure N.M., Chen E.Y., Yeh P., Laderout K.R., and Giaccia A.J. Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression. Cancer Res. 56 (1996) 3436-3440
81. McClure N., Healy D.L., Rogers P.A., Sullivan J., Beaton L., Haning R.J., et al. Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet 344 (1994) 235-236
82. McLaren J., Prentice A., Charnock-Jones D.S., Millican S.A., Muller K.H., Sharkey A.M., et al. Vascular endothelial growth factor is produced by peritoneal fluid macrophages in endometriosis and is regulated by ovarian steroids. J. Clin. Invest. 98 (1996) 482-489
83. McLaren J., Prentice A., Charnock-Jones D.S., and Smith S.K. Vascular endothelial growth factor (VEGF) concentrations are elevated in peritoneal fluid of women with endometriosis. Hum. Reprod. 11 (1996) 220-223
84. Miller J.W., Adamis A.P., Shima D.T., D'Amore P.A., Moulton R.S., O'Reilly M.S., et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am. J. Pathol. 145 (1994) 574-584
85. Minchenko A., Bauer T., Salceda S., and Caro J. Hypoxic stimulation of vascular endothelial growth factor expression in vivo and in vitro. Lab. Invest. 71 (1994) 374-379
86. Mukhopadhyay D., Tsiokas L., and Sukhatme V.P. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res. 55 (1995) 6161-6165
87. Mukhopadhyay D., Tsiokas L., Zhou X.M., Foster D., Brugge J.S., and Sukhatme V.P. Hypoxic induction of vascular endothelial growth factor expression through c-Src activation. Nature 375 (1995) 577-581
88. Nagura S., Katoh R., Miyagi E., Shibuya M., and Kawaoi A. Expression of vascular endothelial growth factor (VEGF) and VEGF Receptor-1 (Flt-1) in Graves disease possibly correlated With increased vascular density. Hum. Pathol. 32 (2001) 10-17
89. O'Brien E.R., Garvin M.R., Dev R., Stewart D.K., Hinohara T., Simpson J.B., et al. Angiogenesis in human coronary atherosclerotic plaques. Am. J. Path. 145 (1994) 883-894
90. Ortéga N., Sordello S., and Plouët J. Vascularisation tumorale : physiopathologie et perspectives thérapeutiques. Bull. Cancer 84 (1997) 391-395
91. Pe'er J., Shweiki D., Itin A., Hemo I., Gnessin H., and Keshet E. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab. Invest. 72 (1995) 638-645
92. Pertovaara L., Kaipainen A., Mustonen T., Orpana A., Ferrara N., Saksela O., et al. Vascular endothelial growth factor is induced in response to transforming growth factor-ß in fibroblastic and epithelial cells. J. Biol. Chem. 269 (1994) 6271-6274
93. Pierce E.A., Avery R.L., Foley E.D., Aiello L.P., and Smith L.E. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc. Natl. Acad. Sci. USA 92 (1995) 905-909
94. Plate K.H., Breier G., Weich H.A., and Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359 (1992) 845-848
95. Polverini P.J. The pathophysiology of angiogenesis. Crit. Rev. Oral Biol. Med. 6 (1995) 230-247
96. Rak J., Mitsuhashi Y., Bayko L., Filmus J., Shirasawa S., Sasazuki T., et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res. 55 (1995) 4575-4580
97. Rini B.I., Tamaskar I., Shaheen P., Salas R., Garcia J., Wood L., et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J. Natl. Cancer Inst. 99 (2007) 81-83
98. Rockwell S., and Knisely J.P.S. Hypoxia and angiogenesis in experimental tumor models: therapeutic implication. In: Goldberg I.D., and Rosen E.M. (Eds). Regulation of angiogenesis (1997), Birkhäuser, Basel, Boston, Berlin 335-360
99. Sato K., Yamazaki K., Shizume K., Kanaji Y., Obara T., Ohsumi K., et al. Stimulation by thyroid-stimulating hormone and Graves' immunoglobulin G of vascular endothelial growth factor mRNA expression in human thyroid follicles in vitro and flt mRNA expression in the rat thyroid in vivo. J. Clin. Invest. 96 (1995) 1295-1302
100. Schoenberger J., Grimm D., Kossmehl P., Infanger M., Kurth E., and Eilles C. Effects of PTK787/ZK222584, a tyrosine kinase inhibitor, on the growth of a poorly differentiated thyroid carcinoma: an animal study. Endocrinology 145 (2004) 1031-1038
101. Senger D.R., Van de Water L., Brown L.F., Nagy J.A., Yeo K.T., Yeo T.K., et al. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev. 12 (1993) 303-324
102. Shifren J.L., Tseng J.F., Zaloudek C.J., Ryan J.P., Meng Y.G., Ferrara N., et al. Ovarian regulation of VEGF in human endometrium: implication for angiogenesis during the menstrual cycle and in the pathogenesis of endometriosis. J. Clin. Endocrinol. Metab. 81 (1996) 3112-3118
103. Siemester G., Weindel K., Mohrs K., Barleon B., Martiny-Baron G., and Marme D. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res. 56 (1996) 2299-2303
104. Soh E., Eigelberger M., Kim K., Wong M., Young D., Clark O., et al. Neutralizing VEGF activity inhibits thyroid cancer growth in vivo. Surgery 128 (2000) 1059-1065
105. Soh E.Y., Duh Q.Y., Sobhi S.A., Young D.M., Epstein H.D., Wong M.G., et al. Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid. J. Clin. Endocrinol. Metab. 82 (1997) 3741-3747
106. Soh E.Y., Sobhi S.A., Wong M.G., Meng Y.G., Siperstein A.E., Clark O.H., et al. Thyroid-stimulating hormone promotes the secretion of vascular endothelial growth factor in thyroid cancer cell lines. Surgery 120 (1996) 944-947
107. Srivastava A., Laidler P., Davies R.P., Horgan K., and Hughes L.E. The prognostic significance of tumor vascularity in intermediate-thickness (0.76-4 mm) skin melanoma. Am. J. Pathol. 133 (1988) 419-422
108. Stavri G.T., Zachary I.C., Breier G., Baskerville P.A., Martin J.F., and Erusalimsky J.D. Basic fibroblast growth factor upregulates the expression of vascular endothelial growth factor in vascular smooth muscle cells. Synergistic action with hypoxia. Circulation 92 (1995) 11-14
109. Tanaka K., Kurebayashi J., Sonoo H., Otsuki T., Yamamoto Y., Ohkubo S., et al. Expression of vascular endothelial growth factor family messenger RNA in diseased thyroid tissues. Surg. Today 32 (2002) 761-768
110. Tannock I.F., and Steel G.G. Quantitative technique for study of the anatomy and function of small blood vessels in tumor. J. Natl. Cancer Inst. 42 (1969) 771-787
111. Tobelem G. L'angiogenèse tumorale. Med. Sci. (Paris) 6 (1990) 426-432
112. Vieira J., Rosa Santos S., Espadinha C., Correia I., Vag T., Casalou C., et al. Expression of vascular endothelial growth factor (VEGF) and its receptors in thyroid carcinomas of follicular origin: a potential autocrine loop. Eur. J. Endocrinol. 153 (2005) 701-709
113. Viglietto G., Maglione D., Rambaldi M., Cerutti J., Romano A., Trapasso F., et al. Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PlGF) associated with malignancy in human thyroid tumors and cell lines. Oncogene 11 (1995) 1569-1579
114. Viglietto G., Romano A., Manzo G., Chiappetta G., Paoletti I., Califano D., et al. Upregulation of the angiogenic factors PlGF, VEGF and their receptors (Flt- 1, Flk-1/KDR) by TSH in cultured thyrocytes and in the thyroid gland of thiouracil-fed rats suggest a TSH-dependent paracrine mechanism for goiter hypervascularization. Oncogene 15 (1997) 2687-2698
115. Wang J.F., Milosveski V., Schramek C., Fong G.H., Becks G.P., and Hill D.J. Presence and possible role of vascular endothelial growth factor in thyroid cell growth and function. J. Endocrinol. 157 (1998) 5-12
116. Warren R.S., Yuan H., Matli M.R., Gillett N.A., and Ferrara N. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J. Clin. Invest. 95 (1995) 1789-1797
117. Weidner N., Carroll P.R., Flax J., Blumenfeld W., and Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am. J. Pathol. 143 (1993) 401-409
118. Weidner N., Semple J.P., Welch W.R., and Folkman J. Tumor angiogenesis: correlation in invasive breast carcinoma. N. Engl. J. Med. 324 (1991) 2-8
119. Weinstat-Saslow D., and Steeg P. Angiogenesis and colonizing in the tumor metastatic process: basic and applied advances. FASEB J. 8 (1994) 401-407
120. Williams B., Baker A.Q., Gallacher B., and Lodwick D. Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells. Hypertension 25 (1995) 913-917
121. Wollman S.H., Herveg J.P., Zelig J.D., and Ericson L.E. Blood capillary enlargement during the development of thyroid hyperplasia in the rat. Endocrinology 102 (1978) 2306-2314
122. Xu G., Pan J., Martin C., and Yeung S.-C. Angiogenesis inhibition in the in vivo antineoplastic effect of manumycin and paclitaxel against anaplastic thyroid carcinoma. J. Clin. Endocrinol. Metab. 86 (2001) 1769-1777
123. Yamazaki K., Abe S., Takekawa H., Sukoh N., Watanabe N., Ogura S., et al. Tumor angiogenesis in human lung adenocarcinoma. Cancer 74 (1994) 2245-2250
124. Yasuoka H., Nakamura Y., Zuo H., Tang W., Takamura Y., Miyauchi A., et al. VEGF-D expression and lymph vessels play an important role for lymph node metastasis in papillary thyroid carcinoma. Mod. Pathol. 18 (2005) 1127-1133
125. Ye C., Feng C., Wang S., Wang K.Z.Q., Huang N., Liu X., et al. sFlt-1 gene therapy of follicular thyroid carcinoma. Endocrinology 145 (2004) 817-822
126. Yeo K.T., Wang H.H., Nagy J.A., Sioussat T.M., Ledbetter S.R., Hoogewerf A.J., et al. Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions. Cancer Res. 53 (1993) 2912-2918
127. Younes M., Yigitbasi O.G., Park Y.W., Kim S.-J., Jasser S.A., Hawthorne V.S., et al. Antivascular therapy of human follicular thyroid cancer experimental bone metastasis by blockade of epidermal growth factor receptor and vascular growth factor receptor phosphorylation. Cancer Res. 65 (2005) 4716-4727
128. Yu X.-M., Lo C.-Y., Chan W.-F., Lam K.-Y., Leung P., and Luk J. Increased expression of vascular endothelial growth factor C in papillary thyroid carcinoma correlates with cervical lymph node metastases. Clin. Cancer Res. 11 (2005) 8063-8069